HC Wainwright Rates uniQure (QURE) buy, $80 Price Target

Analyst Patrick R. Trucchio keeps a buy rating for uniQure with an $80 price target, a 72.32% upside from the current price.

By TradeTexts Research Desk · Published Jun 29, 2026, 7:01 AM EDT · Updated Jul 1, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated uniQure N.V. ($QURE) "buy" with a $80 price target on June 29, 2026.

Since the rating, $QURE is down 12.7% after 1 week, down 15.4% after 1 month and down 54.0% to date (from the $47.39 close on Jun 29, 2026).

QURE uniQure N.V.

$21.78 -6.88% year to date

Daily close · Oct 16, 2026

Key Points

On June 29, 2026, HC Wainwright reiterated its buy rating for uniQure N.V. (QURE) with a price target of $80.
HC Wainwright's $80 price target implies 72.32% upside from uniQure N.V.'s ($QURE) current $46.42 share price.
Shares of NasdaqGS:QURE traded near $47.51 on Monday, with a market cap of approximately $3.27 billion.
Other analysts like Mizuho and Barclays also maintain buy ratings, with targets at $68 and $65 respectively.

Get $QURE trade alerts by text

We text you when insiders, Congress or big funds trade $QURE. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated uniQure N.V. alert may contain errors. Disclosures

HC Wainwright has reiterated its buy rating for uniQure N.V. (NasdaqGS:QURE), maintaining a price target of $80. This update came on June 29, 2026, with analyst Patrick R. Trucchio continuing to support the stock.

Analyst rating track record

HC Wainwright & Co. vs. the S&P 500

YTD return +54.79% hypothetical

All-time return +157.70% S&P 500 +25.98%

vs. S&P 500 +131.72% ahead of the index

Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.

uniQure N.V. Stock Up 121.4%

Shares of uniQure N.V. traded around $47.51 on Monday. The company, which operates in the biotechnology sector, has a market capitalization of about $3.27 billion. While it is not currently profitable, with a forward P/E ratio of -16.11, the stock has shown volatility with a 52-week range between $8.73 and $71.5. uniQure's liquidity is strong, with a current ratio of 10.4 and a quick ratio of 10.0, though it carries a high debt-to-equity ratio of 365.4.

12-month forecast

$QURE price target

uniQure N.V. daily closes and this analyst's $80 target. Not advice.

Recent Earnings

uniQure reported revenue of approximately $18.1 million, seeing a growth of 1.3% from the previous period. However, the company has a negative return on equity of -228.2%, and its net margin stands at zero. Investors are looking ahead to the next earnings report, expected on July 29, 2026.

Insider Buying and Selling at uniQure N.V.

Recently, there have been insider transactions by CEO Matthew Kapusta. On June 25, 2026, Kapusta bought 28,716 shares at $31.71 per share and sold the same amount under a planned sale at $50.02. On June 24, he bought 4,128 shares at $31.71 and sold 6,696 shares at $50.00, also under a planned sale.

Analysts Set New Price Targets

HC Wainwright's recent reiteration of a buy rating for uniQure comes alongside other analysts' views. On June 25, 2026, Mizuho maintained its buy rating with a $68 target. Earlier in June, Barclays upgraded the stock to a buy with a $65 target, while Goldman Sachs held a neutral stance with a $46 target. The consensus among analysts is strong, with a mean target price of $61.68 and a "strong buy" recommendation.

About uniQure N.V.

uniQure N.V. is a biotechnology company based in Amsterdam, Netherlands, focused on developing gene therapies for rare diseases. Its flagship product, HEMGENIX, helps patients with hemophilia B. The company is also working on treatments for Huntington's disease and other conditions. Founded in 1998, uniQure is led by CEO Matthew Craig Kapusta and employs around 221 people.

Bottom Line

uniQure N.V. continues to attract attention from analysts, with HC Wainwright reaffirming its buy rating and setting a high price target. Although the company is not yet profitable, its innovative treatments and strong liquidity position it as a noteworthy player in the biotechnology sector. Investors should remember that analyst ratings are based on past data and market conditions can change.